CWBR CohBar Inc.

1.15
+0.03  (+3%)
Previous Close 1.12
Open 1.12
52 Week Low 0.875
52 Week High 2.27
Market Cap $74,070,344
Shares 43,171,399
Float 50,823,334
Enterprise Value $58,671,255
Volume 746,494
Av. Daily Volume 4,228,479
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
CB4211
Nonalcoholic Fatty Liver Disease / Obesity / Nonalcoholic steatohepatitis
Phase 1b
Phase 1b
Phase 1b top-line data met primary endpoint - August 10, 2021.

Latest News

  1. MENLO PARK, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment of Joanne Yun, Ph.D. as an independent director on the company's Board, effective September 14, 2021. Dr. Yun brings extensive research and development, commercial, and governance experience from the pharmaceutical industry.

    "We are very pleased to add Dr. Yun as an independent director and look forward to her strategic input as we continue to develop our diverse pipeline of novel mitochondria based therapeutics," said David Greenwood, Chairman of CohBar. "Joanne has a wealth of industry experience…

    MENLO PARK, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment of Joanne Yun, Ph.D. as an independent director on the company's Board, effective September 14, 2021. Dr. Yun brings extensive research and development, commercial, and governance experience from the pharmaceutical industry.

    "We are very pleased to add Dr. Yun as an independent director and look forward to her strategic input as we continue to develop our diverse pipeline of novel mitochondria based therapeutics," said David Greenwood, Chairman of CohBar. "Joanne has a wealth of industry experience with a large, impressive network. Her deep understanding of the biotechnology and pharmaceutical industries will provide significant contributions."

    "I am quite excited to join CohBar's Board and believe the company is well positioned to address a number of important medical conditions in need of new therapies," stated Dr. Yun. "CohBar's unique approach to developing novel peptide therapeutics provides multiple independent opportunities for success, with the potential to make a real difference in the lives of patients. I look forward to working closely with the management team and the rest of the Board to advance the company's pipeline and build on the recent success of the positive topline data from the CB4211 clinical trial."

    Dr. Yun is a partner at Egon Zehnder, one of the world's preeminent leadership advisory firms and is currently a member of the firm's Health Practice. In addition to her board and executive leadership work for global pharmaceutical and biotechnology companies, Dr. Yun leads the Research & Development segment of Egon Zehnder's Health Practice.

    Prior to joining Egon Zehnder, Dr. Yun was a Director in the Global Oncology Business Unit for Bayer HealthCare Pharmaceuticals with responsibility for oncology program management and new product planning. She has advised on all aspects of research, development, and commercial strategies, including portfolio prioritization, business development, alliance governance, and merger integration. Dr. Yun started her career with Bayer AG as a Bench Chemist and Laboratory Head in the Organic Synthesis Department of Bayer's Central Research Division in Leverkusen, Germany. She later transitioned into the Corporate Research & Development Planning Department for the Bayer AG Board of Management and then joined the Strategic Planning Department for the Pharmaceuticals Division, where she focused on global merger & acquisition strategies and transactions. Dr. Yun subsequently transferred to Bayer's North America Business Development & Licensing group.

    Dr. Yun earned a bachelor's degree in chemistry and French from Amherst College and a Ph.D. in chemistry from the Massachusetts Institute of Technology. She was a National Institutes of Health (NIH) Postdoctoral Fellow at The Scripps Research Institute and is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the American Chemical Society.

    About CohBar

    CohBar (NASDAQ:CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar's founders of a novel group of naturally occurring peptide sequences within the mitochondrial genome, some of which have been shown to have the potential to regulate key processes in multiple systems and organs in the body. To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs. CohBar's efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases associated with the underlying impact of mitochondrial dysfunction. The company's lead compound, CB4211, which is under development for the treatment of NASH and obesity, recently completed a successful Phase 1a/1b clinical trial. In addition, CohBar has four preclinical programs, the most advanced of which is CB5138-3, a peptide with broad anti-fibrotic and anti-inflammatory properties. This program is currently in IND-enabling studies with the goal of filing an IND and initiating a First-in-Human study in 2022 with an initial indication of idiopathic pulmonary fibrosis. The company also has a program in ARDS, including COVID-19 associated ARDS, as well as two peptide families with potential utility in treating various forms of cancer.

    For additional company information, please visit www.cohbar.com.

    Forward-Looking Statements

    This news release contains forward-looking statements that are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely" or the negative or plural of these words or similar expressions. Examples of such forward-looking statements include but are not limited to statements regarding timing and anticipated outcomes of research and clinical trials for our mitochondria based therapeutic (MBT) candidates; expectations regarding the growth of MBTs as a significant future class of drug products; and statements regarding anticipated therapeutic properties and potential of our mitochondrial peptide analogs, MBTs and other potential therapies. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include: our ability to successfully advance drug discovery and development programs, including the delay or termination of ongoing clinical trials and the timing of announcements and updates relating to our clinical trials and related data; our possible inability to mitigate the prevalence and/or persistence of the injection site reactions, receipt of unfavorable feedback from regulators regarding the safety or tolerability of CB4211 or the possibility of other developments affecting the viability of CB4211 or CB5138-3 as a clinical candidate or its commercial potential; results that are different from earlier data results including less favorable results that may not support further clinical development; our ability to raise additional capital when necessary to continue our operations; our ability to recruit and retain key management and scientific personnel; the risk that our intellectual property may not be adequately protected; our ability to establish and maintain partnerships with corporate and industry partners; and risks related to the impact on our business of the COVID-19 pandemic or similar public health crises. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.

    Contacts:

    Jordyn Tarazi

    Director of Investor Relations

    CohBar, Inc.

    (650) 445-4441

    Jordyn.tarazi@cohbar.com

    Media:

    Nancy Thompson

    Vorticom, Inc.

    (212)532-2208

    Nancyt@vorticom.com



    Primary Logo

    View Full Article Hide Full Article
  2. MENLO PARK, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the United States Patent and Trademark Office has granted a patent, U.S. No. 11,111,271, covering CohBar's lead candidate CB4211 and related compositions, as well as methods of treatment, including methods of treating nonalcoholic steatohepatitis (NASH).

    "The issuance of this patent is a major milestone for CohBar, providing protection for CB4211, our lead clinical asset in the U.S., which recently completed a successful Phase 1a/1b clinical trial as a potential treatment for NASH and obesity," said Dr. Joseph…

    MENLO PARK, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the United States Patent and Trademark Office has granted a patent, U.S. No. 11,111,271, covering CohBar's lead candidate CB4211 and related compositions, as well as methods of treatment, including methods of treating nonalcoholic steatohepatitis (NASH).

    "The issuance of this patent is a major milestone for CohBar, providing protection for CB4211, our lead clinical asset in the U.S., which recently completed a successful Phase 1a/1b clinical trial as a potential treatment for NASH and obesity," said Dr. Joseph Sarret, CEO of CohBar. "We are continuing to execute on our plan to secure comprehensive intellectual property protection for CB4211 and other discoveries from our novel mitochondria based therapeutic technology platform in strategically important markets."

    The term of the new patent extends to at least 2037, not including any patent term extension to which CohBar may be entitled. Should CB4211 be approved in the United States, the new patent would be eligible for listing in the FDA Orange Book.

    The new patent further extends CohBar's growing intellectual property portfolio, which now includes 13 issued patents and more than 65 filed applications directed to novel analogs of mitochondrially encoded peptides and methods of treating a variety of diseases.

    About CB4211

    CB4211, discovered by CohBar scientists, is a first-in-class mitochondria based therapeutic (MBT) under development for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. CB4211 recently demonstrated positive effects on reducing biomarkers of liver injury and improving metabolic homeostasis in a Phase 1a/1b clinical study in obese subjects with nonalcoholic fatty liver disease (NALFD). CB4211 is a novel and improved analog of MOTS-c, a naturally occurring mitochondrial derived peptide (MDP). MOTS-c was discovered in 2012 by CohBar founder Dr. Pinchas Cohen and his academic collaborators and has been shown to play a significant role in the regulation of metabolism in animal models. NASH has been estimated to affect as many as 30 million adults in the U.S., and there is currently no approved treatment for the disease.

    About CohBar

    CohBar (NASDAQ:CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar's founders of a novel group of naturally occurring peptide sequences within the mitochondrial genome, some of which have been shown to have the potential to regulate key processes in multiple systems and organs in the body. To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs. CohBar's efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases associated with the underlying impact of mitochondrial dysfunction. The company's lead compound, CB4211, which is under development for the treatment of NASH and obesity, recently completed a successful Phase 1a/1b clinical trial. In addition, CohBar has four preclinical programs, the most advanced of which is CB5138-3, a peptide with broad anti-fibrotic and anti-inflammatory properties. This program is currently in IND-enabling studies with the goal of filing an IND and initiating a First-in-Human study in 2022 with an initial indication of idiopathic pulmonary fibrosis. The company also has a program in ARDS, including COVID-19 associated ARDS, as well as two peptide families with potential utility in treating various forms of cancer.

    For additional company information, please visit www.cohbar.com.

    Forward-Looking Statements

    This news release contains forward-looking statements that are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely" or the negative or plural of these words or similar expressions. Examples of such forward-looking statements include but are not limited to statements regarding timing and anticipated outcomes of research and clinical trials for our mitochondria based therapeutic (MBT) candidates;  the ability to provide patent protection for our CB4211 program; the potential listing of the patent in the FDA's Orange Book; expectations regarding the growth of MBTs as a significant future class of drug products; and statements regarding anticipated therapeutic properties and potential of our mitochondrial peptide analogs, MBTs and other potential therapies. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include: our ability to successfully advance drug discovery and development programs, including the delay or termination of ongoing clinical trials and the timing of announcements and updates relating to our clinical trials and related data; our possible inability to mitigate the prevalence and/or persistence of the injection site reactions, receipt of unfavorable feedback from regulators regarding the safety or tolerability of CB4211 or the possibility of other developments affecting the viability of CB4211 or CB5138-3 as a clinical candidate or their commercial potential; results that are different from earlier data results including less favorable results that may not support further clinical development; our ability to raise additional capital when necessary to continue our operations; our ability to recruit and retain key management and scientific personnel; the risk that our intellectual property may not be adequately protected; our ability to establish and maintain partnerships with corporate and industry partners; and risks related to the impact on our business of the COVID-19 pandemic or similar public health crises. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.

    Contacts:

    Jordyn Tarazi

    Director of Investor Relations

    CohBar, Inc.

    (650) 445-4441

    Jordyn.tarazi@cohbar.com

    Media:

    Nancy Thompson

    Vorticom, Inc.

    (212)532-2208

    Nancyt@vorticom.com



    Primary Logo

    View Full Article Hide Full Article
  3. MENLO PARK, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the following investor conferences in September.

    H.C. Wainwright Annual Global Investment Conference
    September 13 – 15, 2021
    Webcast: The presentation may be accessed via webcast on demand using the following link: https://journey.ct.events/view/ca7b4b79-1e8b-4452-b5d2-db8298a7f923

    Cantor Fitzgerald Virtual Global Healthcare Conference
    Thursday, September 30, 2021 at 2:00pm ET
    Webcast: The presentation may be accessed via…

    MENLO PARK, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the following investor conferences in September.

    H.C. Wainwright Annual Global Investment Conference

    September 13 – 15, 2021

    Webcast: The presentation may be accessed via webcast on demand using the following link: https://journey.ct.events/view/ca7b4b79-1e8b-4452-b5d2-db8298a7f923

    Cantor Fitzgerald Virtual Global Healthcare Conference

    Thursday, September 30, 2021 at 2:00pm ET

    Webcast: The presentation may be accessed via webcast at the scheduled time, or following the presentation, using the following link: https://wsw.com/webcast/cantor12/cwbr/2083340

    A replay of the webcasts will be available in the events section of the CohBar website for two weeks following the presentation.

    About CohBar

    CohBar (NASDAQ:CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar's founders of a novel group of naturally occurring mitochondrial-derived peptides within the mitochondrial genome that regulate metabolism and cell death, and whose biological activity declines with age. To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs. CohBar's efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases, including nonalcoholic steatohepatitis (NASH), obesity, fibrotic diseases, cancer, acute respiratory distress syndrome (ARDS), type 2 diabetes, and cardiovascular and neurodegenerative diseases. The company's lead compound, CB4211, which is under development for the treatment of NASH and obesity, recently completed a successful Phase 1a/1b clinical trial. In addition, CohBar has four preclinical programs, the most advanced of which is CB5138-3, a peptide with broad anti-fibrotic and anti-inflammatory properties. This program is currently in IND-enabling studies with the goal of filing an IND and initiating a First-in-Human study in 2022 with an initial indication of idiopathic pulmonary fibrosis. The company also has a program in ARDS, including COVID-19 associated ARDS, as well as two peptide families with potential utility in treating various forms of cancer.

    Forward-Looking Statements

    This news release contains forward-looking statements that are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely" or the negative or plural of these words or similar expressions. Examples of such forward-looking statements include but are not limited to statements regarding timing and anticipated outcomes of research and clinical trials for our mitochondria based therapeutic (MBT) candidates; expectations regarding the growth of MBTs as a significant future class of drug products; and statements regarding anticipated therapeutic properties and potential of our mitochondrial peptide analogs, MBTs and other potential therapies. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include: our ability to successfully advance drug discovery and development programs, including the delay or termination of ongoing clinical trials and the timing of announcements and updates relating to our clinical trials and related data; our possible inability to mitigate the prevalence and/or persistence of the injection site reactions, receipt of unfavorable feedback from regulators regarding the safety or tolerability of CB4211 or the possibility of other developments affecting the viability of CB4211 or CB5138-3 as a clinical candidate or its commercial potential; results that are different from earlier data results including less favorable results that may not support further clinical development; our ability to raise additional capital when necessary to continue our operations; our ability to recruit and retain key management and scientific personnel; the risk that our intellectual property may not be adequately protected; our ability to establish and maintain partnerships with corporate and industry partners; and risks related to the impact on our business of the COVID-19 pandemic or similar public health crises. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com

    You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.

    Contacts:

    Jordyn Tarazi

    Director of Investor Relations

    CohBar, Inc.

    (650) 445-4441

    Jordyn.tarazi@cohbar.com

    Media:

    Nancy Thompson

    Vorticom, Inc.

    (212)532-2208

    Nancyt@vorticom.com



    Primary Logo

    View Full Article Hide Full Article
  4. MENLO PARK, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment of Carol Nast as an independent director on the company's Board, effective August 11, 2021. Ms. Nast has spent her career in executive level positions with both large multinational companies and early-stage companies in the medical industry.

    "We are pleased to welcome Carol during this exciting time in CohBar's development," said David Greenwood, Chairman of CohBar. "She brings substantial commercial and operational expertise that will benefit the company as we make further progress in developing…

    MENLO PARK, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment of Carol Nast as an independent director on the company's Board, effective August 11, 2021. Ms. Nast has spent her career in executive level positions with both large multinational companies and early-stage companies in the medical industry.

    "We are pleased to welcome Carol during this exciting time in CohBar's development," said David Greenwood, Chairman of CohBar. "She brings substantial commercial and operational expertise that will benefit the company as we make further progress in developing our novel platform of mitochondria based therapeutics. Carol's insights will be important contributions towards ensuring CohBar's continued success."

    "CohBar is undertaking pioneering work for the treatment of unmet medical needs through its diverse pipeline of novel therapeutics," stated Carol Nast. "This is a particularly exciting time to join the Board following the positive topline data from the CB4211 clinical study. I look forward to supporting the company's numerous opportunities to leverage its platform to develop new therapeutic products as CohBar's pipeline continues to advance."

    Most recently, Ms. Nast served as Chief Operating Officer at MindMed, a biotech company developing psychedelic-inspired therapies. She is a recognized expert in product development and commercialization and has extensive experience in the management of complex, multinational partner programs and has played a critical role in the development and commercialization of over 100 products.

    Previously, Ms. Nast was COO at NuGen, a genomics company, and served in executive level positions at Inhale Therapeutics (Nektar), Syva (a division of Syntex Pharmaceuticals,) BioRad and Pfizer.

    About CohBar

    CohBar (NASDAQ:CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar's founders of a novel group of naturally occurring peptide sequences within the mitochondrial genome, some of which have been shown to have the potential to regulate key processes in multiple systems and organs in the body. To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs. CohBar's efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases associated with the underlying impact of mitochondrial dysfunction. The company's lead compound, CB4211, recently completed a Phase 1a/1b clinical trial for nonalcoholic steatohepatitis (NASH) and obesity. In addition, CohBar has four preclinical programs with the most advanced being CB5138-3 for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, which is currently in IND-enabling studies. The preclinical programs also include the CB5064 Analogs for acute respiratory distress syndrome (ARDS) including COVID-19 associated ARDS, CB5046 Analogs for CXCR4-related cancer and orphan diseases, and MBT3 Analogs for cancer immunotherapy.

    For additional company information, please visit www.cohbar.com.

    Forward-Looking Statements

    This news release contains forward-looking statements that are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely" or the negative or plural of these words or similar expressions. Examples of such forward-looking statements include but are not limited to statements regarding timing and anticipated outcomes of research and clinical trials for our mitochondria based therapeutic (MBT) candidates; expectations regarding the growth of MBTs as a significant future class of drug products; and statements regarding anticipated therapeutic properties and potential of our mitochondrial peptide analogs, MBTs and other potential therapies. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include: our ability to successfully advance drug discovery and development programs, including the delay or termination of ongoing clinical trials and the timing of announcements and updates relating to our clinical trials and related data; our possible inability to mitigate the prevalence and/or persistence of the injection site reactions, receipt of unfavorable feedback from regulators regarding the safety or tolerability of CB4211 or the possibility of other developments affecting the viability of CB4211 or CB5138-3 as a clinical candidate or its commercial potential; results that are different from earlier data results including less favorable results that may not support further clinical development; our ability to raise additional capital when necessary to continue our operations; our ability to recruit and retain key management and scientific personnel; the risk that our intellectual property may not be adequately protected; our ability to establish and maintain partnerships with corporate and industry partners; and risks related to the impact on our business of the COVID-19 pandemic or similar public health crises. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.

    Contacts:

    Jordyn Tarazi

    Director of Investor Relations

    CohBar, Inc.

    (650) 445-4441

    Jordyn.tarazi@cohbar.com



    Primary Logo

    View Full Article Hide Full Article
  5. MENLO PARK, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial results for the second quarter ended June 30, 2021.

    "Our positive CB4211 topline data announcement today marks an important milestone in our path towards demonstrating the full potential of our novel therapeutic platform sourced from the mitochondrial genome," stated Dr. Joseph Sarret, Chief Executive Officer. "In parallel with our ongoing analysis of the promising data from the CB4211 study, we are diligently working to enable CB5138-3 to enter the clinic next year for the treatment of idiopathic…

    MENLO PARK, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial results for the second quarter ended June 30, 2021.

    "Our positive CB4211 topline data announcement today marks an important milestone in our path towards demonstrating the full potential of our novel therapeutic platform sourced from the mitochondrial genome," stated Dr. Joseph Sarret, Chief Executive Officer. "In parallel with our ongoing analysis of the promising data from the CB4211 study, we are diligently working to enable CB5138-3 to enter the clinic next year for the treatment of idiopathic pulmonary fibrosis. This is an exciting time for the company as we look forward to continued progress in the development of product candidates designed to address serious unmet medical needs."

    Second Quarter 2021 and Recent Highlights

    • Announced Positive Topline Data from the Phase 1a/1b Study of CB4211 Being Developed for the Treatment of Nonalcoholic Steatohepatitis (NASH) and Obesity: Today, the company announced topline results from the multi-center, randomized, double-blind, placebo-controlled Phase 1a/1b clinical study of CB4211, under development for NASH and obesity. The study met its primary endpoints as CB4211 was well-tolerated and appeared safe with no serious adverse events. The evaluation of the exploratory endpoints showed robust and statistically significant improvements in key biomarkers of liver damage, ALT and AST, and in glucose levels in the CB4211 group compared to placebo. There was a trend towards lower body weight in the CB4211 group after four weeks of treatment.
    • Appointed Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and Director: In April, the company announced the appointment of Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and Director. Dr. Sarret is a seasoned executive with a track record of success in biotechnology.

    Second Quarter 2021 Financial Highlights

    • Cash and Investments: CohBar had cash and investments of $13.8 million as of June 30, 2021, compared to $21 million as of December 31, 2020. The cash burn for the quarter ended June 30, 2021, was approximately $4.6 million.

    • R&D Expenses: Research and development expenses were $2.6 million for the three months ended June 30, 2021, compared to $1.5 million in the prior year quarter. The increase in research and development expenses was primarily due to the investment in the company's research programs focused on the continued development of its peptides, and an increase in clinical trial costs due to the timing of those expenses, partially offset by a decrease in stock based compensations costs.

    • G&A Expenses: General and administrative expenses were $2.6 million for the three months ended June 30, 2021, compared to $1.4 million in the prior year quarter.  The increase in general and administrative expenses was primarily due to higher compensation and stock-based compensation costs and increased D&O insurance premiums.    

    • Net Loss: For the three months ended June 30, 2021, net loss, which included $1.0 million of non-cash expenses, was $5.2 million, or $0.08 per basic and diluted share. For the three months ended June 30, 2020, net loss, which included $1.8 million of non-cash expenses, was $4.1 million, or $0.09 per basic and diluted share.

    Second Quarter Investor Call:

    Date: August 10, 2021

    Time: 5:00 p.m. ET (2:00 p.m. PT)

    Conference Audio

    • Dial-in U.S. and Canada: (877) 300-8521
    • Dial-in International: (412) 317-6026
    • Conference ID No.: 10159293

    Slide Presentation

    For individuals participating in the Investor Call and Slide Presentation, please call into the conference audio and log into Zoom approximately 10 minutes prior to its start. Please note, no audio will be available through Zoom.

    An audio replay of the call will be available beginning at 8:00 p.m. Eastern Time on August 10, 2021, through 11:59 p.m. Eastern Time on August 31, 2021. To access the recording please dial (844) 512-2921 in the U.S. and Canada, or (412) 317-6671 internationally, and reference Conference ID# 10159293. The audio recording along with the slide presentation will also be available at www.cohbar.com during the same period.

    About CohBar

    CohBar (NASDAQ:CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar's founders of a novel group of naturally occurring peptide sequences within the mitochondrial genome, some of which have been shown to have the potential to regulate key processes in multiple systems and organs in the body. To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs. CohBar's efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases associated with the underlying impact of mitochondrial dysfunction. The company's lead compound, CB4211, recently completed a Phase 1a/1b clinical trial for NASH and obesity. In addition, CohBar has four preclinical programs with the most advanced being CB5138-3 for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, which is currently in IND-enabling studies. The preclinical programs also include the CB5064 Analogs for acute respiratory distress syndrome (ARDS) including COVID-19 associated ARDS, CB5046 Analogs for CXCR4-related cancer and orphan diseases, and MBT3 Analogs for cancer immunotherapy.

    For additional company information, please visit www.cohbar.com.

    Forward-Looking Statements

    This news release contains forward-looking statements that are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely" or the negative or plural of these words or similar expressions. Examples of such forward-looking statements include but are not limited to statements regarding timing and anticipated outcomes of research and clinical trials for our mitochondria based therapeutic (MBT) candidates; expectations regarding the growth of MBTs as a significant future class of drug products; and statements regarding anticipated therapeutic properties and potential of our mitochondrial peptide analogs, MBTs and other potential therapies. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include: our ability to successfully advance drug discovery and development programs, including the delay or termination of ongoing clinical trials and the timing of announcements and updates relating to our clinical trials and related data; our possible inability to mitigate the prevalence and/or persistence of the injection site reactions, receipt of unfavorable feedback from regulators regarding the safety or tolerability of CB4211 or the possibility of other developments affecting the viability of CB4211 or CB5138-3 as a clinical candidate or its commercial potential; results that are different from earlier data results including less favorable results that may not support further clinical development; our ability to raise additional capital when necessary to continue our operations; our ability to recruit and retain key management and scientific personnel; the risk that our intellectual property may not be adequately protected; our ability to establish and maintain partnerships with corporate and industry partners; and risks related to the impact on our business of the COVID-19 pandemic or similar public health crises. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com.

    You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.

    Contacts:

    Jordyn Tarazi

    Director of Investor Relations

    CohBar, Inc.

    (650) 445-4441

    Jordyn.tarazi@cohbar.com



    CohBar, Inc.
    Condensed Balance Sheets
         
       As of
      June 30, 2021 December 31, 2020
      (unaudited)  
                                                         ASSETS    
    Current assets:    
    Cash $1,603,151  $2,894,575 
    Investments  12,221,227   18,120,266 
    Prepaid expenses and other current assets  1,045,848   413,692 
    Total current assets  14,870,226   21,428,533 
    Property and equipment, net  328,078   394,004 
    Intangible assets, net  17,535   18,075 
    Other assets  69,620   67,403 
    Total assets $15,285,459  $21,908,015 
         
    LIABILITIES AND STOCKHOLDERS' EQUITY     
    Current liabilities:    
    Accounts payable $1,858,409  $727,599 
    Accrued liabilities  186,021   1,141,741 
    Accrued payroll and other compensation  731,817   853,335 
    Note payable, net of debt discount and offering costs of $17,441 and $15,656 as of June 30, 2021 and    
    December 31, 2020, respectively  357,559   349,344 
    Total current liabilities  3,133,806   3,072,019 
    Notes payable, net of debt discount and offering costs of $0 and $26,159 as of June 30, 2021 and    
    December 31, 2020, respectively  -   348,841 
    Total liabilities  3,133,806   3,420,860 
         
    Commitments and contingencies    
         
    Stockholders' equity:    
    Preferred stock, $0.001 par value, Authorized 5,000,000 shares;    
    No shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively  -   - 
    Common stock, $0.001 par value, Authorized 180,000,000 shares;    
    Issued and outstanding 62,269,427 shares as of June 30, 2021 and 61,117,524 as of December 31, 2020  62,269   61,118 
    Additional paid-in capital  90,609,379   87,684,323 
    Accumulated deficit  (78,519,995)  (69,258,286)
    Total stockholders' equity  12,151,653   18,487,155 
    Total liabilities and stockholders' equity $15,285,459  $21,908,015 
         



    CohBar, Inc.
    Condensed Statements of Operations
    (unaudited)
             
      For The Three Months Ended June 30,  For The Six Months Ended June 30,
       2021   2020   2021   2020 
             
    Revenues $-  $-  $-  $- 
             
    Operating expenses:        
    Research and development  2,617,675   1,545,043   5,272,447   2,994,915 
    General and administrative  2,584,364   1,390,671   3,943,043   3,222,292 
    Total operating expenses  5,202,039   2,935,714   9,215,490   6,217,207 
    Operating loss  (5,202,039)  (2,935,714)  (9,215,490)  (6,217,207)
             
    Other income (expense):        
    Interest income  (33)  1,743   3,140   37,195 
    Interest expense  (10,425)  (77,837)  (24,985)  (155,673)
    Equity modification expense  -   (998,643)  -   (1,801,043)
    Amortization of debt discount and offering costs  (10,868)  (92,078)  (24,374)  (183,361)
    Total other expense  (21,326)  (1,166,815)  (46,219)  (2,102,882)
    Net loss $(5,223,365) $(4,102,529) $(9,261,709) $(8,320,089)
    Basic and diluted net loss per share $(0.08) $(0.09) $(0.15) $(0.19)
    Weighted average common shares outstanding - basic and diluted  61,860,023   43,336,953   61,710,979   43,228,161 
             


    Primary Logo

    View Full Article Hide Full Article
View All CohBar Inc. News